… The immunomodulatory drugs (IMiDs) lenalidomide and actimid (also known as CC-4047) …
with rituximab, we have previously demonstrated that IMiDs have synergistic in vivo anti-…

… In an attempt to define the role of NK cell expansion in the synergistic effects observed
when rituximab is combined with CC-4047 or CC-5013, we did a second set of in vivo …

… immunomodulatory drugs.6, 7 In our patients, with rituximab as the only immunomodulatory
agent, we assessed the effect of B-lymphocyte depletion on in vivo primary and recall …

… new class of antitumor agents known not only as immunomodulatory agents that enhance the
… Rituximab (Rituxan, RTX) is a genetically engineered murine/human chimeric monoclonal …

… -free combination of ibrutinib, rituximab and lenalidomide in DLBCL and MCL, indicating
that careful study design, toxicity management and in vivo drug activity could allow such …

Rituximab is a chimeric monoclonal antibody employed for … The immunomodulatory activity
of rituximab is closely related … two products containing rituximab. The physicochemical and …

… Expansion of regulatory T-cells (Tregs) following rituximab therapy … rituximab. Recent
CIBMTR data on reduced cumulative incidence of acute GVHD in patients who had prior rituximab …

… of Rituximab in vivo is … of Rituximab to kill B-NHL cells in vitro and in vivo. The latter signalling
pathways are attractive targets for pharmacologic modulation of resistance to Rituximab. …

… , which mediated CD20 crosslinking and induced apoptosis in vitro and in vivo 16 . We
named the designed platform “drug-free macromolecular therapeutics” because it does not …

… rituximab action. However, these in vitro data were not predictive of rituximab efficacy in vivo
in a … signals that overturn rituximab effect, administering immunomodulatory drugs, such as …